Cayman Δ8-Thcva-A; 5 Mg; 63953-77-5; ≥98%

Droxidopa (L-DOPS) is a synthetic precursor and prodrug of the neurotransmitter norepinephrine. It is transformed into norepinephrine through the action of DOPA decarboxylase. L-DOPS increases norepinephrine levels in the rat heart following intraperitoneal administration and in the brain following intracerebroventricular administration at doses of 125 and 100 µg/animal, respectively. It increases arterial pressure and mesenteric arterial resistance in rats with ligated portal vein or biliary ducts when used at doses of 25-50 mg/kg. L-DOPS crosses the blood brain barrier, however, its effects can be blocked by the peripherally-restricted DOPA decarboxylase inhibitor carbidopa (Item No. ), indicating that the mechanism is peripheral.^, Formulations containing droxidopa are used in the treatment of neurogenic orthostatic hypotension.

WARNING This product is not for human or veterinary use.